PELTHOS THERAPEUTICS INC (PTHS) Fundamental Analysis & Valuation

NYSEARCA:PTHS • US1711262048

Current stock price

25 USD
-0.09 (-0.36%)
Last:

This PTHS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. PTHS Profitability Analysis

1.1 Basic Checks

  • In the past year PTHS has reported negative net income.
  • PTHS had a negative operating cash flow in the past year.
  • In the past 5 years PTHS always reported negative net income.
  • PTHS had a negative operating cash flow in each of the past 5 years.
PTHS Yearly Net Income VS EBIT VS OCF VS FCFPTHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • PTHS has a Return On Assets of -18.65%. This is in the better half of the industry: PTHS outperforms 76.31% of its industry peers.
  • PTHS has a better Return On Equity (-40.48%) than 67.57% of its industry peers.
Industry RankSector Rank
ROA -18.65%
ROE -40.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTHS Yearly ROA, ROE, ROICPTHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

1.3 Margins

  • PTHS has a better Gross Margin (172.93%) than 100.00% of its industry peers.
  • The Profit Margin and Operating Margin are not available for PTHS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 172.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTHS Yearly Profit, Operating, Gross MarginsPTHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PTHS Health Analysis

2.1 Basic Checks

  • PTHS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PTHS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTHS Yearly Shares OutstandingPTHS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PTHS Yearly Total Debt VS Total AssetsPTHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

  • Based on the Altman-Z score of -0.02, we must say that PTHS is in the distress zone and has some risk of bankruptcy.
  • PTHS has a Altman-Z score (-0.02) which is comparable to the rest of the industry.
  • PTHS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.02
ROIC/WACCN/A
WACC9.46%
PTHS Yearly LT Debt VS Equity VS FCFPTHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 -10M -20M -30M

2.3 Liquidity

  • PTHS has a Current Ratio of 2.01. This indicates that PTHS is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.01, PTHS is not doing good in the industry: 77.86% of the companies in the same industry are doing better.
  • PTHS has a Quick Ratio of 1.04. This is a normal value and indicates that PTHS is financially healthy and should not expect problems in meeting its short term obligations.
  • PTHS has a Quick ratio of 1.04. This is amonst the worse of the industry: PTHS underperforms 86.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 1.04
PTHS Yearly Current Assets VS Current LiabilitesPTHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. PTHS Growth Analysis

3.1 Past

  • Measured over the past years, PTHS shows a very strong growth in Revenue. The Revenue has been growing by 142.59% on average per year.
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y142.59%
Sales Q2Q%N/A

3.2 Future

  • PTHS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.65% yearly.
  • Based on estimates for the next years, PTHS will show a very strong growth in Revenue. The Revenue will grow by 71.76% on average per year.
EPS Next Y48.61%
EPS Next 2Y38.68%
EPS Next 3Y31.54%
EPS Next 5Y24.65%
Revenue Next Year266.6%
Revenue Next 2Y158.71%
Revenue Next 3Y115.91%
Revenue Next 5Y71.76%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PTHS Yearly Revenue VS EstimatesPTHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
PTHS Yearly EPS VS EstimatesPTHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. PTHS Valuation Analysis

4.1 Price/Earnings Ratio

  • PTHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTHS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTHS Price Earnings VS Forward Price EarningsPTHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTHS Per share dataPTHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PTHS's earnings are expected to grow with 31.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y31.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTHS Dividend Analysis

5.1 Amount

  • No dividends for PTHS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTHS Fundamentals: All Metrics, Ratios and Statistics

PELTHOS THERAPEUTICS INC

NYSEARCA:PTHS (4/30/2026, 6:40:00 PM)

25

-0.09 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-19
Earnings (Next)N/A
Inst Owners32.92%
Inst Owner Change0.01%
Ins Owners1.32%
Ins Owner Change-0.01%
Market Cap84.00M
Revenue(TTM)16.80M
Net Income(TTM)-23.58M
Analysts83.33
Price Target58.29 (133.16%)
Short Float %3.15%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-546.32%
Min EPS beat(2)-1108.39%
Max EPS beat(2)15.74%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.39%
PT rev (3m)-4.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-38.22%
EPS NY rev (1m)-2.09%
EPS NY rev (3m)-58.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.34%
Revenue NY rev (1m)-3.07%
Revenue NY rev (3m)-9.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.34
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.71
EYN/A
EPS(NY)-9.76
Fwd EYN/A
FCF(TTM)-5.06
FCFYN/A
OCF(TTM)-5.06
OCFYN/A
SpS2.2
BVpS17.34
TBVpS-1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -18.65%
ROE -40.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 172.93%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 1.04
Altman-Z -0.02
F-ScoreN/A
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.56%
EPS Next Y48.61%
EPS Next 2Y38.68%
EPS Next 3Y31.54%
EPS Next 5Y24.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y142.59%
Sales Q2Q%N/A
Revenue Next Year266.6%
Revenue Next 2Y158.71%
Revenue Next 3Y115.91%
Revenue Next 5Y71.76%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63445.4%
EBIT Next 3Y954.79%
EBIT Next 5Y26.74%
FCF growth 1Y-210.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.43%
OCF growth 3YN/A
OCF growth 5YN/A

PELTHOS THERAPEUTICS INC / PTHS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PELTHOS THERAPEUTICS INC (PTHS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PTHS.


What is the valuation status of PELTHOS THERAPEUTICS INC (PTHS) stock?

ChartMill assigns a valuation rating of 1 / 10 to PELTHOS THERAPEUTICS INC (PTHS). This can be considered as Overvalued.


Can you provide the profitability details for PELTHOS THERAPEUTICS INC?

PELTHOS THERAPEUTICS INC (PTHS) has a profitability rating of 2 / 10.